title: Poikilodermatous mycosis fungoides.
abstract: Poikilodermatous mycosis fungoides is a rare form of cutaneous T-cell lymphoma that is characterized clinically by localized or diffuse patches, which consist of telangiectases, mottled hyper- and hypopigmentation, and atrophy. The immunophenotype of neoplastic cells is similar to that observed in classic mycosis fungoides. Therapeutic options used in poikilodermatous and classic mycosis fungoides include both skin-directed and systemic treatments. We present a case of poikilodermatous mycosis fungoides in a 53-year-old woman, who initially presented with erythroderma and who has failed multiple treatment modalities.
authors.affiliation: Department of Dermatology, New York University, New York, NY, USA.
authors.forename: Rachel
authors.initials: R
authors.lastname: Farley-Loftus
authors.forename: Rajni
authors.initials: R
authors.lastname: Mandal
authors.forename: Jo-Ann
authors.initials: JA
authors.lastname: Latkowski
mesh_terms: D017255:Acitretin / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000077610:Bexarotene; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000009:adverse effects / Q000627:therapeutic use; D017496:Hypopigmentation / Q000473:pathology; D016130:Immunophenotyping; D016898:Interferon-alpha / Q000627:therapeutic use; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D013764:Tetrahydronaphthalenes / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014467:Ultraviolet Therapy / Q000009:adverse effects; D000077337:Vorinostat
chemical_list: D000970:Antineoplastic Agents; D006877:Hydroxamic Acids; D016898:Interferon-alpha; D013764:Tetrahydronaphthalenes; D000077337:Vorinostat; D000077610:Bexarotene; D017255:Acitretin